Overview

This trial is active, not recruiting.

Condition prostatic neoplasms
Treatment unspecified
Sponsor Bayer
Start date March 2016
End date December 2016
Trial size 2000 participants
Trial identifier NCT02702908, 18044

Summary

This study aims at estimating the incidence of second primary malignancies as well as the overall survival among metastasized prostate cancer (mPC) and metastasized castrate-resistant prostate cancer (mCRPC) patients not treated with radium-223-dichloride.

United States No locations recruiting
Other Countries No locations recruiting

Study Design

Observational model cohort
Time perspective retrospective
Arm
Prostate cancer patients with bone metastases (mPC)
unspecified
Historical Reference group.
Patients with castration-resistant prostate cancer with bone metastases (mCRPC)
unspecified
Historical Reference group.

Primary Outcomes

Measure
Incidences of Second primary malignancies are characterized by the following ICD-10 codes: C00-C76, C81-C96, D00-D09, D37-D48.
time frame: Up to 10 years

Secondary Outcomes

Measure
Overall survival
time frame: Up to 10 years

Eligibility Criteria

Male participants at least 18 years old.

Inclusion Criteria: - Members of the mPC cohort will have to fulfill all of the following criteria: - Valid information on sex, age and the region of residence - A period of at least 12 months of continuous insurance preceding cohort entry - Diagnosis of PC (ICD-10 Code C61) in the study period (01-Jan-2004 to 31-Dec-2011) - Diagnosis of bone metastases (ICD-10 Code C79.5) in the enrolment period (01-Jan-2005 to 31-Dec-2011) - In addition to the criteria of the mPC cohort, members of the mCRPC will additionally have to fulfill: - One of the following in the enrolment period and before or at the same time with bone metastases - Discontinuation of the initial chemical castration, change of the agent or modality of the Androgen deprivation therapy (ADT), or start of treatment for advanced Prostate cancer (PC) after the primary ADT. - Surgical castration and initiation of ADT treatment - Treatment with medication specific to mCRPC. Exclusion Criteria: - Patients will be excluded from the mPC and from the mCRPC populations if they meet one of the following criteria: - First PC diagnosis later than 2 months after the diagnosis of bone metastases, or - Use of any radiopharmaceuticals for bone metastases (e.g., samarium, strontium, rhenium, radium)

Additional Information

Official title Second Primary Cancers in Patients With Castration Resistant Prostate Cancer (BOCARP)
Description This study aims at estimating the incidence of second primary malignancies as well as the overall survival among mPC and mCRPC patients not treated with radium-223-dichloride. The source of data for this study will be the German Pharmacoepidemiological Research Database (GePaRD). A retrospective cohort study covering the time period from 2004 to 2013 will be conducted. The study population will comprise CRPC patients developing bone metastases. These patients will be followed up for the occurrence of second primary malignancies, end of study, or death due to any cause. As this study serves as a historical control group for a single-arm observational study, incidence rates of second primary malignancies obtained from these studies will be compared by the standardized incidence ratio using results from this study as a reference.
Trial information was received from ClinicalTrials.gov and was last updated in November 2016.
Information provided to ClinicalTrials.gov by Bayer.